(Reuters) -German biotech firm BioNTech has agreed to acquire domestic peer CureVac for about $1.25 billion worth of BioNTech shares, it said on Thursday, to boost its work on new mRNA-based cancer ...
BioNTech is buying fellow German mRNA vaccine developer CureVac in an all-stock transaction that values the acquired biotech at $1.25 billion. The announcement makes no specific mention of onboarding ...
Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...
BioNTech plans to shrink its workforce and manufacturing network, as the German biotech company seeks to cut costs and downsize its footprint after demand for Covid-19 vaccines waned. The move means ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results